These advanced analysers provide next-generation clinical chemistry and immunoassay testing, maximising throughput and efficiency. Currently, verifications are in progress, with a projected go-live date in early 2026. This service improvement aligns with our mission and will offer numerous benefits to end users, including a broader testing repertoire in-house and faster turnaround times.